Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$27.3M Buy
733,280
+6,672
+0.9% +$238K 0.19% 99
2019
Q3
$24.8M Buy
726,608
+47,847
+7% +$1.74M 0.18% 102
2019
Q2
$27.9M Buy
678,761
+13,029
+2% +$517K 0.21% 85
2019
Q1
$26.8M Sell
665,732
-5,075
-0.8% -$203K 0.22% 81
2018
Q4
$27.8M Buy
670,807
+40,662
+6% +$1.69M 0.27% 69
2018
Q3
$26.4M Buy
630,145
+138,922
+28% +$5.35M 0.27% 74
2018
Q2
$16.9M Sell
491,223
-15,087
-3% -$516K 0.23% 85
2018
Q1
$17.1M Sell
506,310
-41,339
-8% -$1.42M 0.23% 84
2017
Q4
$18.8M Buy
547,649
+71,452
+15% +$2.44M 0.25% 77
2017
Q3
$16.1M Buy
476,197
+11,661
+3% +$375K 0.25% 77
2017
Q2
$14.8M Buy
464,536
+17,484
+4% +$551K 0.26% 77
2017
Q1
$14.5M Buy
447,052
+27,065
+6% +$853K 0.29% 65
2016
Q4
$12.9M Sell
419,987
-51,875
-11% -$1.58M 0.29% 70
2016
Q3
$15.2M Buy
471,862
+28,056
+6% +$938K 0.36% 43
2016
Q2
$14.8M Buy
+443,806
New +$14.2M 0.39% 44

Other funds holding PFE

Advisor Group's PFE Position: Q4 2019 in Review

Advisor Group increased its Pfizer (PFE) stake by 0.92% in Q4 2019, buying an estimated $238K and bringing the position to 733,280 shares worth $27.3M. The position accounts for 0.19% of the portfolio, ranked #99.

Advisor Group first reported a position in PFE in Q2 2016 and has held it in 15 quarters since. The position peaked at $27.9M in Q2 2019. 2,524 funds tracked by Wall St. Rank hold PFE as of Q4 2019.

  • Advisor Group held 733,280 shares of Pfizer worth $27.3M as of Q4 2019.
  • Advisor Group bought 6,672 Pfizer shares in Q4 2019, an estimated $238K.
  • Pfizer made up 0.19% of Advisor Group's portfolio in Q4 2019, its #99 holding.
  • Advisor Group first reported a position in Pfizer in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Pfizer position peaked at $27.9M in Q2 2019.
  • 2,524 funds tracked by Wall St. Rank held Pfizer as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.